Here are the featured FDA 483s for the week. You can obtain these at the FDAzilla 483s store here>>
5 FEATURES TO LOOK FOR IN AN FDA FORM-483
A form-483 is the document that FDA issues at the close of an inspection where they identify observations made during the inspection. If no observations have been made, no form 483 is issued. Based on the response submitted by the firm, FDA classifies the inspection as: No Action Indicated (NAI) when no form 483 is issued, Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). In general, where FDA issues a form-483 with observations and the firm’s response is satisfactory, the inspection is classified VAI.
The FR announced availability of the long awaited 10-page FDA draft Guidance on Data Integrity and Compliance with CGMP for comment. I include links to the MHRA guidance HERE and the draft WHO guidance HERE for comparison. The guidance is structured in a Q&A format with a total of 18 questions. This guidance focuses heavily on identifying and citing the predicate rules as they apply to electronic records and data integrity, and for this it is an excellent reference. In my opinion, though, the excessive citation of regulations detracts from the content and provides little insight into FDA’s intent and actual expectations in this area.
FDAzilla is a fast-growing data analytics company that provides documents and data services to FDA-regulated companies in the pharmaceutical, medical drug and consulting industries. Our team is growing to meet the increasing demand for our services. We are seeking a sales administrator to handle the day-to-day administrative needs, sales support, customers service and management support. Someone who is analytical, detail-oriented, a team player, customer-focused, and can multi-task. This is part-time position (15-20 hours a week) with the opportunity to become full-time. Work from home.
by Barbara Unger, FDAzilla GMP Quality Expert
INDIA | IMPORT ALERT 66-40 and Association with Warning Letters Regarding These SitesDetention Without Physical Examination of Drugs from Firms Which Have Not Met Drug GMPs